About Zenas BioPharma, Inc.
https://zenasbio.comZenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
CEO
Leon Oliver Moulder Jr.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SR ONE CAPITAL MANAGEMENT, LP
Shares:4.91M
Value:$110.8M
FMR LLC
Shares:4.82M
Value:$108.75M
ENAVATE SCIENCES GP, LLC
Shares:3.76M
Value:$84.86M
Summary
Showing Top 3 of 80
About Zenas BioPharma, Inc.
https://zenasbio.comZenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $47.58M ▲ | $-51.5M ▲ | 0% | $-1.22 ▲ | $-51.49M ▲ |
| Q2-2025 | $0 ▼ | $12.14M ▼ | $-52.22M ▼ | 0% ▲ | $-1.25 ▼ | $-55.15M ▼ |
| Q1-2025 | $10M ▲ | $47.33M ▼ | $-33.57M ▲ | -335.73% ▲ | $-0.8 ▲ | $-33.76M ▲ |
| Q4-2024 | $5M ▲ | $60.62M ▲ | $-52.6M ▼ | -1.05K% ▼ | $-1.26 ▼ | $-55.59M ▼ |
| Q3-2024 | $0 | $7.45M | $-38.61M | 0% | $-0.92 | $-40.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $290.88M ▲ | $322.02M ▲ | $125.59M ▲ | $196.43M ▼ |
| Q2-2025 | $273.28M ▼ | $293.08M ▼ | $53.46M ▲ | $239.63M ▼ |
| Q1-2025 | $312.38M ▼ | $333.77M ▼ | $49.45M ▼ | $284.32M ▼ |
| Q4-2024 | $350.77M ▼ | $369.97M ▼ | $57.51M ▲ | $312.46M ▼ |
| Q3-2024 | $386.8M | $403.43M | $44M | $359.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-51.5M ▲ | $-41.13M ▲ | $40.04M ▲ | $72.62M ▲ | $71.56M ▲ | $-41.13M ▲ |
| Q2-2025 | $-52.22M ▼ | $-41.74M ▼ | $-112.29M ▼ | $1.72M ▲ | $-152.55M ▼ | $-41.74M ▼ |
| Q1-2025 | $-33.57M ▲ | $-37.05M ▲ | $-86.27M ▼ | $99K ▼ | $-123.28M ▼ | $-37.07M ▲ |
| Q4-2024 | $-52.6M ▼ | $-38.55M ▼ | $-3.73M ▲ | $1.85M ▼ | $-40.3M ▼ | $-38.63M ▼ |
| Q3-2024 | $-38.61M | $-31.06M | $-26.76M | $233.98M | $176.11M | $-31.06M |
CEO
Leon Oliver Moulder Jr.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SR ONE CAPITAL MANAGEMENT, LP
Shares:4.91M
Value:$110.8M
FMR LLC
Shares:4.82M
Value:$108.75M
ENAVATE SCIENCES GP, LLC
Shares:3.76M
Value:$84.86M
Summary
Showing Top 3 of 80